Clinical Trial Update: Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting completion of an immunization strategy using the GP100 peptide vaccine with an ER insertion signal sequence in patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GP100 peptide vaccine preceded by an ER insertion signal sequence (gp100 peptide vaccine with ER insertion signal sequence)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma, Neoplasm Metastasis | Phase 2 | Status: COMPLETED